IMPACT BIOMEDICAL INC. financial data

Symbol
IBO on NYSE
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 10.5 % +8.22%
Debt-to-equity -568 %
Return On Equity 8.09K % +194599%
Return On Assets -228 % -8581%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 105M shares +809%
Common Stock, Shares, Outstanding 12.2M shares +5.92%
Entity Public Float 0 USD
Common Stock, Value, Issued 12K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 12.2M shares +5.92%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 18K USD
Research and Development Expense 122K USD -90.4%
Selling and Marketing Expense 168K USD -66.9%
Costs and Expenses 1.08M USD +21.3%
Operating Income (Loss) -29.3M USD -701%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.2M USD -4122%
Net Income (Loss) Attributable to Parent -44.2M USD -3761%
Earnings Per Share, Basic -3 USD/shares -2531%
Earnings Per Share, Diluted -3 USD/shares -2287%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12K USD -99.6%
Accounts Receivable, after Allowance for Credit Loss, Current 15K USD
Inventory, Net 485K USD
Assets, Current 917K USD -71.1%
Property, Plant and Equipment, Net 13K USD -95.4%
Goodwill 25.1M USD 0%
Assets 18.2M USD -61%
Accounts Payable, Current 576K USD -42.5%
Accrued Liabilities, Current 336K USD +229%
Liabilities, Current 23.8M USD +1991%
Deferred Income Tax Liabilities, Net 3.27M USD +1.02%
Liabilities 27.1M USD +119%
Retained Earnings (Accumulated Deficit) -54.8M USD -418%
Stockholders' Equity Attributable to Parent -11.8M USD -138%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -8.85M USD -126%
Liabilities and Equity 18.2M USD -61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -682K USD -41.5%
Net Cash Provided by (Used in) Financing Activities 483K USD -52.5%
Net Cash Provided by (Used in) Investing Activities 1K USD
Common Stock, Shares Authorized 4B shares 0%
Common Stock, Shares, Issued 12.2M shares +5.92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -681K USD -68200%
Deferred Tax Assets, Gross 4.42M USD +24.3%
Depreciation 1K USD -50%
Property, Plant and Equipment, Gross 30K USD -89.8%
Deferred Tax Assets, Operating Loss Carryforwards 2.95M USD +41.4%
Preferred Stock, Shares Issued 60.5M shares 0%
Preferred Stock, Shares Authorized 100M shares 0%
Additional Paid in Capital 42.9M USD +2.47%
Preferred Stock, Shares Outstanding 60.5M shares 0%
Amortization of Intangible Assets 282K USD +1.44%
Depreciation, Depletion and Amortization 283K USD +1.07%
Interest Expense 1.06M USD +15.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%